ABT
62
9
MAT
60
-5
FITB
52
-4
NUE
50
2
AEP
40
-2
TROW
48
8
NAVI
27
-3
MO
57
-3
CME
53
-3
MLM
60
-7
LOW
46
-2
EQIX
57
-3
FDX
39
-5
PEG
44
-2
VTR
46
-3
VRTX
43
-4
CB
44
-3
DTE
45
-2
MDT
62
3
MCK
59
13
ABT
62
9
MAT
60
-5
FITB
52
-4
NUE
50
2
AEP
40
-2
TROW
48
8
NAVI
27
-3
MO
57
-3
CME
53
-3
MLM
60
-7
LOW
46
-2
EQIX
57
-3
FDX
39
-5
PEG
44
-2
VTR
46
-3
VRTX
43
-4
CB
44
-3
DTE
45
-2
MDT
62
3
MCK
59
13
Financhill
Back

Kiniksa Pharmaceuticals International PLC 10K Form

Sell
39

KNSA
Kiniksa Pharmaceuticals International PLC

Last Price:
21.49
Seasonality Move:
29.58%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KNSA News And Ratings

See the #1 stock for the next 7 days that we like better than KNSA

KNSA Financial Statistics

Sales & Book Value

Annual Sales: $270.26M
Cash Flow: $-2.24M
Price / Cash Flow: 147.35
Annual Sales: $6.06
Price / Book: 3.71

Profitability

EPS (TTM): -0.14000
Net Income (TTM): $-9.07M
Gross Margin: $236.85M
Return on Equity: -2.11%
Return on Assets: -1.73%

Kiniksa Pharmaceuticals International PLC Earnings Forecast

Key Kiniksa Pharmaceuticals International PLC Financial Ratios

  • The Gross Profit Margin over the past 5 years for KNSA is 87.64%.
  • The Selling, General & Administrative Expenses for KNSA have been equal to 47.89% of Gross Profit Margin.
  • The Research & Development expenses have been 28.16% of Revenue.
  • The Net Earning history of KNSA is 5.21% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 4 years.

Kiniksa Pharmaceuticals International PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Current Symbol: KNSA
CUSIP: G5269C
Website: kiniksa.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.24
Quick Ratio: 2.59

Price-to-Earnings

Trailing P/E Ratio: 112.38
Forward P/E Ratio: 28.81

KNSA Technical Analysis vs Fundamental Analysis

Sell
39
Kiniksa Pharmaceuticals International PLC (KNSA) is a Sell

Is Kiniksa Pharmaceuticals International PLC a Buy or a Sell?